News Agency
Men's Weekly

Akeso Announced First Patient Dosed in Phase 3 Trial of Ivonescimab versus Tislelizumab for First-line Treatment of Squamous NSCLC

  • Written by PR Newswire

HONG KONG, Aug. 18, 2023 /PRNewswire/ -- Akeso Inc. ("Akeso", 9926. HK) announced today that the first patient has been dosed in a head-to-head phase III trial of ivonescimab, a potential first-in-class investigational PD-1/VEGF bi-specific antibody discovered by Akeso. The Phase III trial will evaluate the clinical efficacy and assess the safety...

Read more: Akeso Announced First Patient Dosed in Phase 3 Trial of Ivonescimab versus Tislelizumab for...

How Signage Shapes Business Visibility And Customer Perception

In today’s competitive commercial environment, signage is far more than just a display element—it acts as a silent communicator between a business and its audience. Whether positioned outdoors or within a retail or corporate space, it provides immediate information about what... Read more

Writers Wanted



NewsServices.com

Content & Technology Connecting Global Audiences

More Information - Less Opinion